Boston-based Activ Surgical designed ActivSight to provide enhanced visualization and real-time, on-demand surgical insights. The module attaches to laparoscopic and robotic systems and integrates with standard monitors in the operating room. It received CE mark approval for ActivSight in December 2022. The FDA cleared the technology in April 2021.
The company aims to transform the surgical experience using emerging technologies and data. It wants every surgical imaging system to deliver intelligent information, reducing surgical complication rates. Activ Surgical announced the first U.S. case with the AI-enabled platform just over a year ago.
Activ Surgical says its platform transforms the operating room by seamlessly upgrading existing equipment while serving as the “eyes” for the surgeo…